Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-06-06
2011-11-08
Wang, Chang-Yu (Department: 1649)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S449000, C514S459000, C514S079000
Reexamination Certificate
active
08053413
ABSTRACT:
The present invention relates to a method for preventing or ameliorating a sleep-related breathing disorder. The method involves the use of one or a combination of cholecystokinin (CCK) receptor antagonists.
REFERENCES:
patent: 4820834 (1989-04-01), Evans et al.
patent: 5618811 (1997-04-01), Lowe, III
patent: 5688943 (1997-11-01), Ryder et al.
patent: 5728829 (1998-03-01), Semple et al.
patent: 5962451 (1999-10-01), Ryder et al.
patent: 6075033 (2000-06-01), Makovec et al.
patent: 2004/0198723 (2004-10-01), Gibson
Burgess et al. J of Cell Bio. 1990, 111:2129-2138.
Bowie et al. Science, 1990, 247:1306-1310.
Pawson et al. 2003, Science 300:445-452.
Widdop et al., “Electrophysiological and autoradiographical evidence for cholecystokinin A receptors on rat isolated nodose gangila”, J. Autonomic Nervous System 1993 46:65-73.
Yoshioka et al., “Pharmacological Characterization of 5-Hydroxytryptamine-Induced Apnea in the Rat”, J. Pharmacology and Experimental Therapeutics 1992 260(2):917-924.
DeMesquita et al., “Effect of chronic intracerebroventricular infusion of cholecystokinin on respiration and sleep”, Brain Research 1986 378:127-132.
Bennet et al., “Apneic effects of cholecystokinin in unanaesthetized fetal sheep”, Journal of Developmental Physiology 1990 14:229-233.
Herranz, Rosario, “Cholecystokinin Antagonists; Pharmacological and Therapeutic Potential”, Medicinal Research Reviews 2003 23(5) :559-605.
Fourmy et al. “Structure of Cholecystokinin Receptor Binding Sites and Mechanism of Activation/Inactivation by Agonists/Antagonists” Pharmacology & Toxicology 2002 vol. 91: 313-320.
Bock et al. “Cholecystokinin (CCK) Receptor Antagonists” Current Pharmaceutical Design Ed. Graham Johnson 1995 vol. 1(3) : 284-289.
Gales et al. “Identification of Tyrosine 189 and Asparagine 358 of the Cholecystokinin 2 Receptor in Direct Interaction with the Crucial C-Terminal Amide of Cholecystokinin by Molecular Modeling, Site Directed Mutagenesis, and Structure/Affinity Studies” Molecular Pharmacology 2003 vol. 63(5) : 973-982.
Carley David W.
Radulovacki Miodrag
Licata & Tyrrell P.C.
The Board of Trustees of the University of Illinois
Wang Chang-Yu
LandOfFree
Methods for treating sleep disorders by cholecystokinin... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods for treating sleep disorders by cholecystokinin..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treating sleep disorders by cholecystokinin... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4290934